HYPOGAMMAGLOBULINEMIA IN LUNG TRANSPLANT RECIPIENTS

Background. Infectious complications continue to represent a significant source of morbidity and mortality in lung transplant recipients.Identifying specific, remediable immune defects is of potential value. After one lung transplant patient with recurrent infections was noted to be severely hypogammaglobulinemic, a screening program for humoral immune defects was instituted. The objectives were to define the prevalence of hypogammaglobulinemia in lung transplant recipients, assess levels of antibody to specific pathogens, and correlate infectious disease outcomes and survival with immunoglobulin levels. Methods. All lung transplant recipients followed at a single center between October 1996 and June 1999 underwent a posttransplant humoral immune status survey as part of routine posttransplant follow-up. This survey consists of total immunoglobulin levels (IgG, IgM, IgA), IgG subclasses (IgG1–4), and antibody titers to Pneumococcus, diphtheria, and tetanus. Since February 1997, this survey has been incorporated into the pretransplant evaluation as well. Humoral survey results for October 1996 through July 1999 were recorded, and clinical information on major infectious disease outcomes was obtained from chart reviews, discharge summaries, the Cleveland Clinic Unified Transplant Database, and review of all microbiological studies and pathology results for each patient. Results. Of 67 patients with humoral immune surveys drawn posttransplant, 47 (70%) had IgG levels less than 600 mg/dl (normal 717-1410 mg/dl), of which 25 (37%) had IgG levels less than 400 mg/dl (“lowest IgG group”) and 22 (33%) had IgG levels between 400 and 600 mg/dl (“moderately low IgG group”). A total of 20 patients (30%) had IgG levels of more than 600 mg/dl (“normal IgG group”). Infections that were significantly more common in the lowest IgG group, and more common in the moderately low IgG group than the normal IgG group, included: number of pneumonias (P =0.0006), bacteremias (P =0.02), total bacterial infections (P =0.002), tissue-invasive cytomegalovirus (P =0.01), invasive aspergillosis (P =0.001), total fungal infections (P =0.001), and total infections (P =0.006). Median hospital days per posttransplant year was significantly different in the three groups (11.0 vs. 7.4 vs. 2.8 days, P =0.0003.) Invasive aspergillosis occurred in 44% of the lowest IgG group, 9% of the moderately low IgG group, and 0% of the normal IgG group (P <0.001). Survival was poorest in the lowest IgG group and intermediate in the moderately low IgG group. IgG subclass deficiencies occurred in a variety of patterns. Hypogammaglobulinemic patients lacked protective responses to Pneumococcus in 14/47 (30%), diphtheria in 15%, and tetanus in 19%. In a group of 48 patients screened pretransplant, 90% had normal immunoglobulin levels. Conclusions. Hypogammaglobulinemia in lung transplant recipients is more common than has been previously recognized. An IgG level of less than 400 mg/dl identifies a group at extremely high risk of bacterial and fungal infections, tissue-invasive cytomegalovirus, and poorer survival. Immunoglobulin monitoring may offer an opportunity for intensive surveillance, tapering of immunosuppression, and preemptive therapy for infection.

[1]  N. Smedira,et al.  Significant post‐transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  M. Hogan,et al.  Renal transplantation in a patient with common variable immunodeficiency. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  N. Smedira,et al.  HYPOGAMMAGLOBULINEMIA IN HEART TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS, MYCOPHENOLATE, AND PREDNISONE , 1999 .

[4]  B. Griffith,et al.  Clinical significance of CMV-specific T helper responses in lung transplant recipients. , 1998, Human immunology.

[5]  G. Patterson,et al.  Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. , 1998, The Journal of thoracic and cardiovascular surgery.

[6]  J. Gómez-Moreno,et al.  Infection in organ-transplant recipients. , 1998, The New England journal of medicine.

[7]  R. Bolman,et al.  Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  A. Mehta,et al.  Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Snydman,et al.  The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. , 1997, The American journal of medicine.

[10]  R. Bolman,et al.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. , 1997, The Journal of thoracic and cardiovascular surgery.

[11]  W. Braun,et al.  Life after 20 years with a kidney transplant: redefined disease profiles and an emerging nondiabetic vasculopathy. , 1997, Transplantation proceedings.

[12]  A. Mehta,et al.  Cytomegalovirus infection in seromismatched lung transplant recipients with and without prophylaxis with CMV immunoglobulin. , 1996, Transplantation proceedings.

[13]  G. Berry,et al.  Risk factors for the development of obliterative bronchiolitis after lung transplantation. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  B. Griffith,et al.  Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. , 1995, The Journal of thoracic and cardiovascular surgery.

[15]  R. Rubin,et al.  Clinical Approach to Infection in the Compromised Host , 2002, Springer US.

[16]  B. Griffith,et al.  A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. , 1994, American journal of respiratory and critical care medicine.

[17]  R. Rubin Infection in the Organ Transplant Recipient , 1994 .

[18]  E. Spitznagel,et al.  Cytomegalovirus Infection and Pneumonitis: Impact after Isolated Lung Transplantation , 1993 .

[19]  J. Maurer,et al.  Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. , 1993, Transplantation proceedings.

[20]  B. Griffith,et al.  Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. , 1992, The American review of respiratory disease.

[21]  D. V. van Thiel,et al.  THE ASSOCIATION OF IgA DEFICIENCY BUT NOT IgG OR IgM DEFICIENCY WITH A REDUCED PATIENT AND GRAFT SURVIVAL FOLLOWING LIVER TRANSPLANTATION , 1992, Transplantation.

[22]  J. Cooper,et al.  Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. , 1992, The Journal of infectious diseases.

[23]  B. Griffith,et al.  Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. , 1991, Transplantation.

[24]  R. Rubin The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. , 1989, JAMA.

[25]  A. Sheil,et al.  Immunoglobulin abnormalities in renal transplant recipients. , 1989, Transplantation.

[26]  J. Hasbargen,et al.  Hypogammaglobulinemia in a renal transplant recipient with antiglomerular basement membrane disease. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  C. Pearson,et al.  The effect of azathioprine on gammaglobulin synthesis in man. , 1972, Journal of Clinical Investigation.